Merck Highlights Commitment to Improving Cancer Outcomes at ASCO 2023

DARMSTADT, Germany–(BUSINESS WIRE)–Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US. New data for the medicines BAVENCIO® (avelumab), ERBITUX® (cetuximab), and TEPMETKO® (tepotinib) and pipeline assets including the first-in-class investigational IAP (inhibitor of apoptosis protein) inhibitor xevinap
Click here to view original post

Advertise With Biotech Networks

Be the first to comment

Leave a Reply

Your email address will not be published.


*